Matches in Nanopublications for { ?s ?p ?o <http://www.tkuhn.ch/bel2nanopub/RA4-YV1byk5RVHkomu5kmtAzmu8hdqr2sUF2egho8y2v0#provenance>. }
Showing items 1 to 11 of
11
with 100 items per page.
- _5 label "Selventa" provenance.
- large_corpus.bel rights "Copyright (c) 2011-2012, Selventa. All rights reserved." provenance.
- _4 value "Several anticancer therapies target, albeit indirectly, the PI3K/ Akt1 axis and cause inhibition of Akt1 phosphorylation and induction of apoptosis. Examples include herceptin, which inhibits ErbB2 in breast cancer cells; cyclooxygenase-2 (COX-2) inhibitors, which inhibit COX-2 and PDK1 in colon and prostate cancer; gefitnib (Iressa), which targets mutant epidermal growth factor receptor in lung cancer cells; and imatinib mesylate (Gleevec, STI- 571), which targets bcr-abl in leukemia. Conversely, inhibition of anoikis, which contributes to metastasis by trkB or TWIST, involves Akt activation. Given that Akt1 binds to Par-4 in diverse cell types, the action of these therapeutic agents may involve regulation of Par-4 function via Akt1." provenance.
- _4 wasQuotedFrom 16540633 provenance.
- assertion hadPrimarySource 16540633 provenance.
- large_corpus.bel title "BEL Framework Large Corpus Document" provenance.
- large_corpus.bel description "Approximately 61,000 statements." provenance.
- assertion wasDerivedFrom _4 provenance.
- assertion wasDerivedFrom large_corpus.bel provenance.
- large_corpus.bel authoredBy _5 provenance.
- large_corpus.bel version "1.4" provenance.